Ponatinib Produces Higher Rates of Minimal Residual Disease-Negative Complete Remission in Ph+ ALL
November 17th 2022Ponatinib (Iclusig; Takeda) combined with reduced-intensity chemotherapy achieved higher minimal residual disease-negative complete remission rates in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia compared to imatinib.
Read More
Novel Migraine Treatment Shows Mixed Results in Phase 3 Efficacy Trial
November 16th 2022Investigational migraine drug produces significant effects on both freedom-from-pain and MBS-free endpoints at 3 hours post administration and at additional efficacy measurement timepoints of 4, 6, 12, 24 and 48 hours.
Read More
Research Continues Evaluating Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
November 14th 2022Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.
Read More
FDA Approves Menveo Single-Vial Presentation for Disease Caused by Meningococcal Bacteria
October 17th 2022New presentation offers health care providers with a more convenient, ready-to-use immunization option for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
Read More
Zanubrutinib Shows Superior Progression-Free Survival vs Ibrutinib in Chronic Lymphocytic Leukemia
October 13th 2022Zanubrutinib (Brukinsa) is a small molecule Bruton’s tyrosine kinase inhibitor under evaluation as a monotherapy and in combination with other treatments for various B-cell malignancies.
Read More
FDA Approves Furosemide Injection for Congestion in Patients with Chronic Heart Failure
October 10th 2022Furosemide injection 80 mg/10 mL (Furoscix; scPharmaceuticals) is indicated for the at-home treatment of congestion caused by fluid overload in adult patients with New York Heart Association Class II/III chronic heart failure.
Read More
FDA Grants Accelerated Approval to Futibatinib for Locally Advanced, Metastatic Cholangiocarcinoma
October 3rd 2022Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.
Read More
Combination of Ivosidenib Plus Azacitidine Produces Survival Benefit in Acute Myeloid Leukemia
September 30th 2022Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.
Read More
FDA Approves Bevacizumab Biosimilar for Six Types of Cancer
September 28th 2022Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More